Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

450 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Non-Hodgkin's lymphomas, version 2.2014.
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Zelenetz AD, et al. Among authors: gordon li. J Natl Compr Canc Netw. 2014 Jun;12(6):916-46. doi: 10.6004/jnccn.2014.0086. J Natl Compr Canc Netw. 2014. PMID: 24925202
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA. Witzig TE, et al. Among authors: gordon li. J Clin Oncol. 2002 May 15;20(10):2453-63. doi: 10.1200/JCO.2002.11.076. J Clin Oncol. 2002. PMID: 12011122 Clinical Trial.
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.
Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-López AJ, White CA. Wiseman GA, et al. Among authors: gordon li. Blood. 2002 Jun 15;99(12):4336-42. doi: 10.1182/blood.v99.12.4336. Blood. 2002. PMID: 12036859 Free article. Clinical Trial.
Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
Schilder R, Molina A, Bartlett N, Witzig T, Gordon L, Murray J, Spies S, Wang H, Wiseman G, White C. Schilder R, et al. Cancer Biother Radiopharm. 2004 Aug;19(4):478-81. doi: 10.1089/cbr.2004.19.478. Cancer Biother Radiopharm. 2004. PMID: 15453962 Clinical Trial.
450 results